Clinical Trials Logo

TRAPS clinical trials

View clinical trials related to TRAPS.

Filter by:
  • None
  • Page 1

NCT ID: NCT05292768 Not yet recruiting - FMF Clinical Trials

Are Mast Cells Involved in Autoinflammatory Diseases

INFLAMAST
Start date: March 2022
Phase:
Study type: Observational

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).Our aim is to evaluate the involvement of MC in AID by assessing clinical and biological signs of MC activation and studying cutaneous and digestive biopsies.

NCT ID: NCT00442182 Recruiting - Clinical trials for Autoinflammatory Syndromes

The Efficacy and Safety of ITF2357 in AIS

Start date: September 2006
Phase: Phase 2
Study type: Interventional

Autoinflammatory syndromes (AIS) are a group of disorders characterized by recurrent episodes of inflammation.Although for the hereditary autoinflammatory diseases the genetic mutations are known it remains largely unclear how these mutations lead to recurrent inflammatory attacks. Treatment of the inflammatory symptoms remains a challenge. With beneficial responses reported during treatment with simvastatin, etanercept or anakinra in some but not all patients. ITF2357 is an orally active histon deacetylase inhibitor with a potent anti-inflammatory effect due to inhibition of pro-inflammatory cytokines (IL-1β, TNFα, IFNg, IL-6). We expect that ITF2357 is able to modify the clinical symptoms of AIS patients and induce clinical complete remission or a reduction in attack duration.